z-logo
Premium
Late‐onset Epstein–Barr virus‐related disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation is associated with impaired early recovery of T and B lymphocytes
Author(s) -
Liu Jiangying,
Yan Chenhua,
Zhang Chunli,
Xu Lanping,
Liu Yanrong,
Huang Xiaojun
Publication year - 2015
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.12593
Subject(s) - medicine , immunophenotyping , hematopoietic stem cell transplantation , transplantation , leukemia , cd8 , acute leukemia , immunology , stem cell , cohort , gastroenterology , immune system , flow cytometry , biology , genetics
Epstein–Barr virus‐related disease (EBVD) is a serious clinical complication in patients who have undergone haploidentical hematopoietic stem cell transplantation (haploHSCT). Some recipients develop EBVD relatively late after haploHSCT, and most of these patients suffer a poor outcome. This retrospective cohort study characterized the early adaptive immune recovery of patients with acute leukemia presenting with EBVD more than 100 d after haploHSCT. Patients with acute leukemia who received haploHSCT and developed EBVD 100 d later (n = 8) were compared with a matched control group without EBVD (n = 24) with regard to peripheral WBC, lymphocytes, and neutrophils (at 30, 60, and 90 d) and recoveries of B and T lymphocytes (at 30 and 90 d, via immunophenotyping/flow cytometry). Ninety days after haploHSCT, the median values of WBCs and lymphocytes, and the recoveries of CD19 + B cells and CD4 + , CD8 + , and CD4 + CD45RO + T cells, were significantly lower in patients who developed EBVD, relative to the control group. These results suggest a significant association between deficient early recovery of B and T lymphocytes and the development of late‐onset EBVD after haploHSCT. Our observation could facilitate clinical intervention and the improvement of overall survival of patients undergoing haploHSCT.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here